Efficacy and tolerance of antiretroviral therapy in HIV-2 infected patients in Dakar: Preliminary study;Évaluation de l'efficacité et de la tolérance du traitement antirétroviral chez des patients infectés par le VIH-2 à Dakar: Étude pŕliminaire

Medecine et Maladies Infectieuses

Volumn 36, Issue 2, 2006, Pages 111-114

  Ndour, C T ^a   Batista, G ^a   Manga, N M ^a   Ngom Gueye N F ^a   Dia Badiane, N M ^a   Fortez, L ^a   Sow, P S ^a  

^a Centre Hospitalier Universitaire Dakar   (Senegal)

Author keywords

HAART; HIV 2; Senegal

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; AIDS RELATED COMPLEX; CD4 LYMPHOCYTE COUNT; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; RETROSPECTIVE STUDY; SENEGAL; TREATMENT OUTCOME;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HIV-2; HUMANS; RETROSPECTIVE STUDIES; SENEGAL; TREATMENT OUTCOME;

EID: 33644511081     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.medmal.2005.11.012     Document Type: Article

References (10)

1. F. Simon, S. Matheron, C. Tamalet, I. Loussert-Ajaka, S. Bartczak, and J.M. Pepin Cellular and plasma viral load in patients infected with HIV-2 AIDS 7 1993 1411 1417
2. R. Marlink, P. Kanki, I. Thior, K. Travers, G. Eisen, and T. Siby Reduced rate of disease development after HIV-2 infection as compared to HIV-1 Science 265 1994 1587 1590
3. T. Rubinek, J.B. McMahon, and A. Hizi Inhibition of reverse transcriptase of human immunodeficiency virus type 1 and type 2 by two novel non-nucleoside inhibitors FEBBS Lett 330 1994 299 303
4. C.A. Adj́-Touŕ, R. Cheinsong, J.G. Garcia-Lerma, S. Eholí, M.Y. Borget, and J.M. Bouchez Antiretroviral therapy in HIV-2 infected patients: changes in plasma viral load, CD4+ cell count, and drug resistance profiles of patients treated in Abidjan AIDS 17 suppl 3 2003 S49 S54
5. H.B. Fung, H.L. Kirscenbaum, and R. Hameed Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor Clin. Ther. 22 2000 549 572
6. C. Laurent, N. Diakhat́, N.F. Ngom Gùye, M.A. Touŕ, P.S. Sow, and M.A. Faye The senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study AIDS 16 2002 1363 1370
7. M.E. Van Der Ende, J.M. Prins, K. Brinkman, M. Keuter, J. Veenstra, and S.A. Danner Clinical, immunological and virological response to different antiretroviral regimens in a cohortnof HIV-2-infected patients AIDS 17 suppl 3 2003 S55 S61
8. N.A. Smith, T. Shaw, N. Berry, C. Vella, L. Okorafor, and D. Taylor Antiretroviral therapy for HIV-2 infected patients J. Infect. 42 2001 126 133
9. A. Carr, K. Samaras, D.J. Chisholm, and D.A. Cooper Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia and insulin ressistance Lancet 351 1998 1881 1883
10. A.S. Mallal, M. John, C.B. Moore, I.R. James, and E.J. McKinnon Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection AIDS 14 2000 33 38